Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

101. CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. (Full text)

CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. 21288101 2011 02 10 2018 12 01 1533-4406 364 5 2011 02 03 The New England journal of medicine N. Engl. J. Med. CYP2C19 genotype and outcomes of clopidogrel treatment. 481-2 10.1056/NEJMc1013331 Siasos Gerasimos G Tousoulis Dimitris D Stefanadis Christodoulos C eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors 9035-51-2 Cytochrome P-450 Enzyme System A74586SNO7 Clopidogrel EC 1.14.14.1 Aryl (...) Hydrocarbon Hydroxylases EC 1.14.14.1 CYP2C19 protein, human EC 1.14.14.1 Cytochrome P-450 CYP2C19 EC 1.14.14.1 Cytochrome P-450 CYP3A OM90ZUW7M1 Ticlopidine AIM IM N Engl J Med. 2010 Oct 28;363(18):1704-14 20979470 Acute Coronary Syndrome drug therapy Aryl Hydrocarbon Hydroxylases genetics Clopidogrel Cytochrome P-450 CYP2C19 Cytochrome P-450 CYP3A metabolism Cytochrome P-450 Enzyme System genetics Humans Mutation Platelet Aggregation Inhibitors therapeutic use Ticlopidine analogs & derivatives

2011 NEJM PubMed

103. CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. (Full text)

CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. 21288102 2011 02 10 2018 12 01 1533-4406 364 5 2011 02 03 The New England journal of medicine N. Engl. J. Med. CYP2C19 genotype and outcomes of clopidogrel treatment. 481; author reply 482 10.1056/NEJMc1013331 Geisler Tobias T Bigalke Boris B Schwab Matthias M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Platelet Aggregation Inhibitors A74586SNO7 Clopidogrel EC 1.14.14.1 Aryl Hydrocarbon Hydroxylases EC 1.14.14.1 (...) CYP2C19 protein, human EC 1.14.14.1 Cytochrome P-450 CYP2C19 OM90ZUW7M1 Ticlopidine AIM IM N Engl J Med. 2010 Oct 28;363(18):1704-14 20979470 Acute Coronary Syndrome drug therapy Aryl Hydrocarbon Hydroxylases genetics Atrial Fibrillation drug therapy Clopidogrel Cytochrome P-450 CYP2C19 Genotype Humans Mutation Platelet Aggregation Inhibitors therapeutic use Risk Factors Ticlopidine analogs & derivatives therapeutic use 2011 2 4 6 0 2011 2 4 6 0 2011 2 11 6 0 ppublish 21288102 10.1056/NEJMc1013331

2011 NEJM PubMed

104. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (Full text)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke (...) , but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control.we analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76-1.03), all-cause mortality (HR: 0.82

2011 EvidenceUpdates PubMed

105. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) (PubMed)

Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg). However, the applicability of these data to stable patients who undergo elective (...) percutaneous coronary intervention is still unclear. A total of 400 patients who underwent elective PCI were prospectively randomized to receive either 600 mg (n = 200) or 300 mg (n = 200) of clopidogrel, followed by a daily maintenance dose of 75 mg. The primary end point was the presence of major adverse cardiovascular events (combined death, myocardial infarction, acute neurologic event, stent thrombosis, and need for percutaneous or surgical revascularization of the target vessel) during

2011 EvidenceUpdates

106. Plavix (clopidogrel bisulfate)

Plavix (clopidogrel bisulfate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Plavix (clopidogrel bisulfate) 75 mg Tablets Company: sanofi-aventis U.S. LLC Application No.: 020839s051 Approval Date: 05/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

2011 FDA - Drug Approval Package

107. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. (Full text)

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. The US Food and Drug Administration recently recommended that CYP2C19 genotyping be considered prior to prescribing clopidogrel, but the American Heart Association and American College of Cardiologists have argued evidence is insufficient to support CYP2C19 genotype testing.To appraise evidence on the association of CYP2C19 genotype and clopidogrel response through (...) systematic review and meta-analysis.PubMed and EMBASE from their inception to October 2011.Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included.We extracted information on study design, genotyping, and disease outcomes and investigated sources of bias.We retrieved 32 studies of 42,016 patients reporting 3545 CVD events, 579 stent thromboses, and 1413 bleeding

2011 JAMA PubMed

108. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. (Full text)

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined.To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI.Randomized (...) , double-blind, active-control trial (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety [GRAVITAS]) of 2214 patients with high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents at 83 centers in North America between July 2008 and April 2010.High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months.The primary end point was the 6-month incidence of death from

2011 JAMA PubMed

109. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. (Full text)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. To evaluate efficacy and safety outcomes in patients in the PLATelet inhibition and patient Outcomes (PLATO) trial who at randomisation were planned for a non-invasive treatment strategy.Pre-specified analysis of pre-randomisation defined subgroup of prospective randomised clinical trial.862 (...) centres in 43 countries.5216 (28%) of 18,624 patients admitted to hospital for acute coronary syndrome who were specified as planned for non-invasive management.Randomised treatment with ticagrelor (n=2601) versus clopidogrel (2615).Primary composite end point of cardiovascular death, myocardial infarction, and stroke; their individual components; and PLATO defined major bleeding during one year.2183 (41.9%) patients had coronary angiography during their initial hospital admission, 1065 (20.4%) had

2011 BMJ PubMed

110. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. (Full text)

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial (...) that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily.Platelet function test results

2011 JAMA PubMed

111. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin

Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Xie X, McGregor M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Xie X (...) , McGregor M. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin. Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC). Report no. 53. 2011 Authors' conclusions • The applicant intends to use the VerifyNow test to detect those patients at increased risk of arterial thrombotic events due to Clopidogrel resistance. Patients found to be clopidogrel resistant will be treated with other thienopyridine drugs. • The VerifyNow test is easy

2011 Health Technology Assessment (HTA) Database.

112. Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel | BMJ Evidence-Based Medicine We use cookies (...) Username * Password * your user name or password? You are here Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Article Text Prognosis Systematic review Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention

2011 Evidence-Based Medicine (Requires free registration)

113. Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct

Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with … Article Text Therapeutics Randomised controlled trial Percutaneous coronary intervention for acute coronary syndromes: no difference

2011 Evidence-Based Medicine (Requires free registration)

114. Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding

Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers

2011 Evidence-Based Medicine (Requires free registration)

115. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies (Full text)

Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Nijjer SS, Watson G (...) , Athanasiou T, Malik IS CRD summary This review found that patients with acute coronary syndrome who required urgent coronary artery bypass graft surgery could proceed with surgery without a washout period delay to cease clopidogrel use. Methodological flaws mean the results should be interpreted with caution and the authors' conclusion is uncertain. Authors' objectives To determine the risk of mortality, reoperation, perioperative myocardial infarction, and stroke in patients with acute coronary syndrome

2011 DARE. PubMed

116. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Technology Report Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary (...) Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses Issue 133 November 2010Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Cite as: Banerjee S, Brown A, McGahan L, Asakawa K, Hutton B, Clark M, Severn M, Sharma M, Cox JL. Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome

2011 EvidenceUpdates

117. Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis

Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

118. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

119. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

120. Clopidogrel Teva Pharma B.V.

Clopidogrel Teva Pharma B.V. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. EMA/439548/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Clopidogrel Teva Pharma B.V. International non proprietary name (...) : clopidogrel Procedure No. EMEA/H/C/001226 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product no longer authorisedTable of contents Page 1. Background information on the procedure 3 1.1. Submission of the dossier 3 Scientific Advice: 3 Licensing status: 4 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 6 2.2.1. Introduction 6 2.2.2. Active Substance 6 2.2.3

2011 European Medicines Agency - EPARs